Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Oruka Therapeutics, Inc.ORKA · Entity 3781 | Director | June 11, 2026 | June 12, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Oruka Therapeutics, Inc.
Report date June 11, 2026 · Filed June 12, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 38,743 |
Ending reported balance
After 2026-06-12 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-06-11 · Sale · Disposed 22,417 · Balance 51,326 F1: These sales were effected pursuant to a Rule 10b5-1 trading plan entered into on February 19, 2026. F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $70.00 to $70.65, inclusive. The reporting person undertakes to provide to Oruka Therapeutics, Inc., any security holder of Oruka Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) and (3) to this Form 4. Row 2 · 2026-06-12 · Sale · Disposed 12,583 · Balance 38,743 F1: These sales were effected pursuant to a Rule 10b5-1 trading plan entered into on February 19, 2026. F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $70.00 to $70.50, inclusive. |
Filing footnotes · ownership attribution and instrument terms
F1: These sales were effected pursuant to a Rule 10b5-1 trading plan entered into on February 19, 2026.
F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $70.00 to $70.65, inclusive. The reporting person undertakes to provide to Oruka Therapeutics, Inc., any security holder of Oruka Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) and (3) to this Form 4.
F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $70.00 to $70.50, inclusive.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Apogee Therapeutics, Inc.
Report date September 02, 2026 · Filed September 03, 2026
Section 16 reporting ended · disclosed 2026-09-03. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Ending reported balance
After 2026-09-03 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-09-02 · Disposition to issuer · Disposed 1,375 · Balance 167,123 Row 2 · 2026-09-03 · Disposition to issuer · Disposed 167,123 · Balance 0 F1: The reported securities represent shares of the Issuer's common stock disposed of pursuant to the terms of the Agreement and Plan of Merger, dated as of June 18, 2026 (the "Merger Agreement"), among Andor LLC, Andor Merger Co., the Issuer and AbbVie Inc. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $22.86 · Expires 2033-12-18 | Direct | 0 |
Reported balance
After 2026-09-03 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-09-03 · Disposition to issuer · Disposed 110,665 · Balance 0 F3: Each reported option was disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the per share merger consideration of $135.11 over the exercise price of such option. F2: The reported options were vested as of the date of the Merger or became fully vested in connection with the Merger. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $49.07 · Expires 2034-12-09 | Direct | 0 |
Reported balance
After 2026-09-03 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-09-03 · Disposition to issuer · Disposed 124,962 · Balance 0 F3: Each reported option was disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the per share merger consideration of $135.11 over the exercise price of such option. F2: The reported options were vested as of the date of the Merger or became fully vested in connection with the Merger. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $75.78 · Expires 2036-01-02 | Direct | 0 |
Reported balance
After 2026-09-03 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2026-09-03 · Disposition to issuer · Disposed 83,690 · Balance 0 F3: Each reported option was disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the per share merger consideration of $135.11 over the exercise price of such option. F2: The reported options were vested as of the date of the Merger or became fully vested in connection with the Merger. |
Filing footnotes · ownership attribution and instrument terms
F1: The reported securities represent shares of the Issuer's common stock disposed of pursuant to the terms of the Agreement and Plan of Merger, dated as of June 18, 2026 (the "Merger Agreement"), among Andor LLC, Andor Merger Co., the Issuer and AbbVie Inc.
F2: The reported options were vested as of the date of the Merger or became fully vested in connection with the Merger.
F3: Each reported option was disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the per share merger consideration of $135.11 over the exercise price of such option.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 03, 2026 Filed Sep 3, 2026 20:39 UTC | Apogee Therapeutics, Inc. APGE · Entity 1939 | Disposition to issuerStock Option (Right to Buy) · Derivative | 83,690 | Not disclosed Strike: $75.78 | Not disclosed |
DisclosureSEC source: 0001140361-26-035613 · form4.xml · derivative · entry 5 Dambkowski Carl · CIK 0001983476 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 83,690 shares Expires 2036-01-02 F3 · price: Each reported option was disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the per share merger consideration of $135.11 over the exercise price of such option. F2 · derivative.exercise_date: The reported options were vested as of the date of the Merger or became fully vested in connection with the Merger. F3 · derivative.exercise_date: Each reported option was disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the per share merger consideration of $135.11 over the exercise price of such option. Read SEC document |
| September 03, 2026 Filed Sep 3, 2026 20:39 UTC | Apogee Therapeutics, Inc. APGE · Entity 1939 | Disposition to issuerStock Option (Right to Buy) · Derivative | 124,962 | Not disclosed Strike: $49.07 | Not disclosed |
DisclosureSEC source: 0001140361-26-035613 · form4.xml · derivative · entry 4 Dambkowski Carl · CIK 0001983476 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 124,962 shares Expires 2034-12-09 F3 · price: Each reported option was disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the per share merger consideration of $135.11 over the exercise price of such option. F2 · derivative.exercise_date: The reported options were vested as of the date of the Merger or became fully vested in connection with the Merger. F3 · derivative.exercise_date: Each reported option was disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the per share merger consideration of $135.11 over the exercise price of such option. Read SEC document |
| September 03, 2026 Filed Sep 3, 2026 20:39 UTC | Apogee Therapeutics, Inc. APGE · Entity 1939 | Disposition to issuerStock Option (Right to Buy) · Derivative | 110,665 | Not disclosed Strike: $22.86 | Not disclosed |
DisclosureSEC source: 0001140361-26-035613 · form4.xml · derivative · entry 3 Dambkowski Carl · CIK 0001983476 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 110,665 shares Expires 2033-12-18 F3 · price: Each reported option was disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the per share merger consideration of $135.11 over the exercise price of such option. F2 · derivative.exercise_date: The reported options were vested as of the date of the Merger or became fully vested in connection with the Merger. F3 · derivative.exercise_date: Each reported option was disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the per share merger consideration of $135.11 over the exercise price of such option. Read SEC document |
| September 03, 2026 Filed Sep 3, 2026 20:39 UTC | Apogee Therapeutics, Inc. APGE · Entity 1939 | Disposition to issuerCommon Stock | 167,123 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001140361-26-035613 · form4.xml · nonDerivative · entry 2 Dambkowski Carl · CIK 0001983476 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · shares: The reported securities represent shares of the Issuer's common stock disposed of pursuant to the terms of the Agreement and Plan of Merger, dated as of June 18, 2026 (the "Merger Agreement"), among Andor LLC, Andor Merger Co., the Issuer and AbbVie Inc. F1 · price: The reported securities represent shares of the Issuer's common stock disposed of pursuant to the terms of the Agreement and Plan of Merger, dated as of June 18, 2026 (the "Merger Agreement"), among Andor LLC, Andor Merger Co., the Issuer and AbbVie Inc. Read SEC document |
| September 02, 2026 Filed Sep 3, 2026 20:39 UTC | Apogee Therapeutics, Inc. APGE · Entity 1939 | Disposition to issuerCommon Stock | 1,375 | $135.06 | $185,707.50 |
DisclosureSEC source: 0001140361-26-035613 · form4.xml · nonDerivative · entry 1 Dambkowski Carl · CIK 0001983476 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 167,123 Read SEC document |
| August 05, 2026 Filed Aug 8, 2026 00:00 UTC | Apogee Therapeutics, Inc. APGE · Entity 1939 | Exercise / conversionStock Option (Right to Buy) · Derivative | 4,125 | $0.00 Strike: $22.86 | $0.00 |
DisclosureSEC source: 0001104659-26-092838 · tm2622546-1_4seq1.xml · derivative · entry 3 Dambkowski Carl · CIK 0001983476 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 110,665 Underlying: Common Stock · 4,125 shares Expires 2033-12-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: This option represents the right to purchase 175,345 shares of the Issuer's common stock, which will vest in forty-eight equal monthly installments through December 18, 2027, subject to the Reporting Person's continued service to the Issuer. Read SEC document |
| August 05, 2026 Filed Aug 8, 2026 00:00 UTC | Apogee Therapeutics, Inc. APGE · Entity 1939 | SaleCommon Stock | 5,500 | $134.17 | $737,935.00 |
DisclosureSEC source: 0001104659-26-092838 · tm2622546-1_4seq1.xml · nonDerivative · entry 2 Dambkowski Carl · CIK 0001983476 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 168,498 F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 22, 2025. Read SEC document |
| August 05, 2026 Filed Aug 8, 2026 00:00 UTC | Apogee Therapeutics, Inc. APGE · Entity 1939 | Exercise / conversionCommon Stock | 4,125 | $22.86 | $94,297.50 |
DisclosureSEC source: 0001104659-26-092838 · tm2622546-1_4seq1.xml · nonDerivative · entry 1 Dambkowski Carl · CIK 0001983476 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 173,998 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 14, 2026 Filed Jul 17, 2026 00:00 UTC | Apogee Therapeutics, Inc. APGE · Entity 1939 | GiftCommon Stock | 8,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-26-084344 · tm2620587-1_4seq1.xml · nonDerivative · entry 1 Dambkowski Carl · CIK 0001983476 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 169,873 F1 · kind: This transaction involves a bona fide gift of securities from the reporting person to a donor advised fund. Read SEC document |
| July 01, 2026 Filed Jul 3, 2026 00:13 UTC | Apogee Therapeutics, Inc. APGE · Entity 1939 | Exercise / conversionStock Option (Right to Buy) · Derivative | 4,125 | $0.00 Strike: $22.86 | $0.00 |
DisclosureSEC source: 0001104659-26-080477 · tm2619720-1_4seq1.xml · derivative · entry 3 Dambkowski Carl · CIK 0001983476 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 114,790 Underlying: Common Stock · 4,125 shares Expires 2033-12-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: This option represents the right to purchase 175,345 shares of the Issuer's common stock, which will vest in forty-eight equal monthly installments through December 18, 2027, subject to the Reporting Person's continued service to the Issuer. Read SEC document |
| July 01, 2026 Filed Jul 3, 2026 00:13 UTC | Apogee Therapeutics, Inc. APGE · Entity 1939 | SaleCommon Stock | 5,500 | $132.74 | $730,070.00 |
DisclosureSEC source: 0001104659-26-080477 · tm2619720-1_4seq1.xml · nonDerivative · entry 2 Dambkowski Carl · CIK 0001983476 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 177,873 F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 22, 2025. Read SEC document |
| July 01, 2026 Filed Jul 3, 2026 00:13 UTC | Apogee Therapeutics, Inc. APGE · Entity 1939 | Exercise / conversionCommon Stock | 4,125 | $22.86 | $94,297.50 |
DisclosureSEC source: 0001104659-26-080477 · tm2619720-1_4seq1.xml · nonDerivative · entry 1 Dambkowski Carl · CIK 0001983476 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 183,373 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 22, 2026 Filed Jun 25, 2026 00:01 UTC | Apogee Therapeutics, Inc. APGE · Entity 1939 | SaleCommon Stock | 26,400 | $132.60 | $3,500,640.00 |
DisclosureSEC source: 0001104659-26-077427 · tm2618514-1_4seq1.xml · nonDerivative · entry 1 Dambkowski Carl · CIK 0001983476 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 179,248 F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 22, 2025. F2 · price: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $132.550 to $132.645, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| June 12, 2026 Filed Jun 12, 2026 20:36 UTC | Oruka Therapeutics, Inc. ORKA · Entity 3781 | SaleCommon Stock | 12,583 | $70.11 | $882,181.55 |
DisclosureSEC source: 0000907654-26-000054 · form4.xml · nonDerivative · entry 2 Dambkowski Carl · CIK 0001983476 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 38,743 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan entered into on February 19, 2026. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $70.00 to $70.50, inclusive. Read SEC document |
| June 11, 2026 Filed Jun 12, 2026 20:36 UTC | Oruka Therapeutics, Inc. ORKA · Entity 3781 | SaleCommon Stock | 22,417 | $70.13 | $1,572,200.60 |
DisclosureSEC source: 0000907654-26-000054 · form4.xml · nonDerivative · entry 1 Dambkowski Carl · CIK 0001983476 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 51,326 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan entered into on February 19, 2026. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $70.00 to $70.65, inclusive. The reporting person undertakes to provide to Oruka Therapeutics, Inc., any security holder of Oruka Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) and (3) to this Form 4. Read SEC document |
| June 03, 2026 Filed Jun 6, 2026 00:00 UTC | Apogee Therapeutics, Inc. APGE · Entity 1939 | Exercise / conversionStock Option (Right to Buy) · Derivative | 4,125 | $0.00 Strike: $22.86 | $0.00 |
DisclosureSEC source: 0001104659-26-071076 · tm2616980-1_4seq1.xml · derivative · entry 3 Dambkowski Carl · CIK 0001983476 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 118,915 Underlying: Common Stock · 4,125 shares Expires 2033-12-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: This option represents the right to purchase 175,345 shares of the Issuer's common stock, which will vest in forty-eight equal monthly installments through December 18, 2027, subject to the Reporting Person's continued service to the Issuer. Read SEC document |
| June 03, 2026 Filed Jun 6, 2026 00:00 UTC | Apogee Therapeutics, Inc. APGE · Entity 1939 | SaleCommon Stock | 5,500 | $78.71 | $432,905.00 |
DisclosureSEC source: 0001104659-26-071076 · tm2616980-1_4seq1.xml · nonDerivative · entry 2 Dambkowski Carl · CIK 0001983476 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 205,648 F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 22, 2025. Read SEC document |
| June 03, 2026 Filed Jun 6, 2026 00:00 UTC | Apogee Therapeutics, Inc. APGE · Entity 1939 | Exercise / conversionCommon Stock | 4,125 | $22.86 | $94,297.50 |
DisclosureSEC source: 0001104659-26-071076 · tm2616980-1_4seq1.xml · nonDerivative · entry 1 Dambkowski Carl · CIK 0001983476 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 211,148 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 02, 2026 Filed Jun 3, 2026 20:52 UTC | Oruka Therapeutics, Inc. ORKA · Entity 3781 | GrantStock Option (right to buy) · Derivative | 9,136 | $0.00 Strike: $55.23 | $0.00 |
DisclosureSEC source: 0000907654-26-000052 · form4.xml · derivative · entry 1 Dambkowski Carl · CIK 0001983476 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,136 Underlying: Common Stock · 9,136 shares Expires 2036-06-01 F1 · derivative.exercise_date: The option vests as to 1/12 of the underlying shares monthly from June 2, 2026. Read SEC document |
| May 21, 2026 Filed May 22, 2026 20:54 UTC | Oruka Therapeutics, Inc. ORKA · Entity 3781 | Exercise / conversionStock Option (right to buy) · Derivative | 11,667 | $0.00 Strike: $11.77 | $0.00 |
DisclosureSEC source: 0000907654-26-000043 · form4.xml · derivative · entry 9 Dambkowski Carl · CIK 0001983476 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 5,833 Underlying: Common Stock · 11,667 shares Expires 2035-06-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_date: The option vests as to 1/12 of the shares underlying the option monthly from June 2, 2025. Read SEC document |
| May 21, 2026 Filed May 22, 2026 20:54 UTC | Oruka Therapeutics, Inc. ORKA · Entity 3781 | Exercise / conversionWarrant (right to buy) · Derivative | 11,904 | $0.00 Strike: $7.80 | $0.00 |
DisclosureSEC source: 0000907654-26-000043 · form4.xml · derivative · entry 8 Dambkowski Carl · CIK 0001983476 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 10,952 Underlying: Common Stock · 11,904 shares Expires 2034-07-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: The option vests as to 25% of the shares underlying the option on April 3, 2025, and as to 1/48 of the shares underlying the option monthly thereafter. Read SEC document |
| May 21, 2026 Filed May 22, 2026 20:54 UTC | Oruka Therapeutics, Inc. ORKA · Entity 3781 | Exercise / conversionStock Option (right to buy) · Derivative | 38,689 | $0.00 Strike: $6.84 | $0.00 |
DisclosureSEC source: 0000907654-26-000043 · form4.xml · derivative · entry 7 Dambkowski Carl · CIK 0001983476 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 32,737 Underlying: Common Stock · 38,689 shares Expires 2034-05-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The option vests as to 25% of the shares underlying the option on March 1, 2025, and as to 1/48 of the shares underlying the option monthly thereafter. Read SEC document |
| May 21, 2026 Filed May 22, 2026 20:54 UTC | Oruka Therapeutics, Inc. ORKA · Entity 3781 | SaleCommon Stock | 13,235 | $59.97 | $793,661.92 |
DisclosureSEC source: 0000907654-26-000043 · form4.xml · nonDerivative · entry 6 Dambkowski Carl · CIK 0001983476 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 73,743 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan entered into on February 19, 2026. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $59.71 to $60.31, inclusive. Read SEC document |
| May 21, 2026 Filed May 22, 2026 20:54 UTC | Oruka Therapeutics, Inc. ORKA · Entity 3781 | SaleCommon Stock | 53,447 | $59.10 | $3,158,910.11 |
DisclosureSEC source: 0000907654-26-000043 · form4.xml · nonDerivative · entry 5 Dambkowski Carl · CIK 0001983476 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 86,978 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan entered into on February 19, 2026. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $58.71 to $59.70, inclusive. Read SEC document |
| May 21, 2026 Filed May 22, 2026 20:54 UTC | Oruka Therapeutics, Inc. ORKA · Entity 3781 | SaleCommon Stock | 38,318 | $58.43 | $2,238,794.29 |
DisclosureSEC source: 0000907654-26-000043 · form4.xml · nonDerivative · entry 4 Dambkowski Carl · CIK 0001983476 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 140,425 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan entered into on February 19, 2026. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $57.71 to $58.70, inclusive. The reporting person undertakes to provide to Oruka Therapeutics, Inc., any security holder of Oruka Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (3) and (4) to this Form 4. Read SEC document |
| May 21, 2026 Filed May 22, 2026 20:54 UTC | Oruka Therapeutics, Inc. ORKA · Entity 3781 | Exercise / conversionCommon Stock | 11,667 | $11.77 | $137,320.59 |
DisclosureSEC source: 0000907654-26-000043 · form4.xml · nonDerivative · entry 3 Dambkowski Carl · CIK 0001983476 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 178,743 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 21, 2026 Filed May 22, 2026 20:54 UTC | Oruka Therapeutics, Inc. ORKA · Entity 3781 | Exercise / conversionCommon Stock | 11,904 | $7.80 | $92,851.20 |
DisclosureSEC source: 0000907654-26-000043 · form4.xml · nonDerivative · entry 2 Dambkowski Carl · CIK 0001983476 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 167,076 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 21, 2026 Filed May 22, 2026 20:54 UTC | Oruka Therapeutics, Inc. ORKA · Entity 3781 | Exercise / conversionCommon Stock | 38,689 | $6.84 | $264,632.76 |
DisclosureSEC source: 0000907654-26-000043 · form4.xml · nonDerivative · entry 1 Dambkowski Carl · CIK 0001983476 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 155,172 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 06, 2026 Filed May 9, 2026 00:00 UTC | Apogee Therapeutics, Inc. APGE · Entity 1939 | Exercise / conversionStock Option (Right to Buy) · Derivative | 4,125 | $0.00 Strike: $22.86 | $0.00 |
DisclosureSEC source: 0001104659-26-058129 · tm2613976-1_4seq1.xml · derivative · entry 4 Dambkowski Carl · CIK 0001983476 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 123,040 Underlying: Common Stock · 4,125 shares Expires 2033-12-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: This option represents the right to purchase 175,345 shares of the Issuer's common stock, which will vest in forty-eight equal monthly installments through December 18, 2027, subject to the Reporting Person's continued service to the Issuer. Read SEC document |
| May 06, 2026 Filed May 9, 2026 00:00 UTC | Apogee Therapeutics, Inc. APGE · Entity 1939 | SaleCommon Stock | 1,800 | $84.60 | $152,280.00 |
DisclosureSEC source: 0001104659-26-058129 · tm2613976-1_4seq1.xml · nonDerivative · entry 3 Dambkowski Carl · CIK 0001983476 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 207,023 F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 22, 2025. F3 · price: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $84.44 to $84.69, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| May 06, 2026 Filed May 9, 2026 00:00 UTC | Apogee Therapeutics, Inc. APGE · Entity 1939 | SaleCommon Stock | 3,700 | $83.92 | $310,504.00 |
DisclosureSEC source: 0001104659-26-058129 · tm2613976-1_4seq1.xml · nonDerivative · entry 2 Dambkowski Carl · CIK 0001983476 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 208,823 F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 22, 2025. F2 · price: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $83.35 to $84.28, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission ("SEC"), upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| May 06, 2026 Filed May 9, 2026 00:00 UTC | Apogee Therapeutics, Inc. APGE · Entity 1939 | Exercise / conversionCommon Stock | 4,125 | $22.86 | $94,297.50 |
DisclosureSEC source: 0001104659-26-058129 · tm2613976-1_4seq1.xml · nonDerivative · entry 1 Dambkowski Carl · CIK 0001983476 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 212,523 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 01, 2026 Filed Apr 4, 2026 00:00 UTC | Apogee Therapeutics, Inc. APGE · Entity 1939 | Exercise / conversionStock Option (Right to Buy) · Derivative | 4,125 | $0.00 Strike: $22.86 | $0.00 |
DisclosureSEC source: 0001104659-26-039709 · tm2611042-1_4seq1.xml · derivative · entry 5 Dambkowski Carl · CIK 0001983476 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 127,165 Underlying: Common Stock · 4,125 shares Expires 2033-12-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: This option represents the right to purchase 175,345 shares of the Issuer's common stock, which will vest in forty-eight equal monthly installments through December 18, 2027, subject to the Reporting Person's continued service to the Issuer. Read SEC document |
| April 01, 2026 Filed Apr 4, 2026 00:00 UTC | Apogee Therapeutics, Inc. APGE · Entity 1939 | SaleCommon Stock | 100 | $85.89 | $8,589.00 |
DisclosureSEC source: 0001104659-26-039709 · tm2611042-1_4seq1.xml · nonDerivative · entry 4 Dambkowski Carl · CIK 0001983476 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 208,398 F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 22, 2025. Read SEC document |
| April 01, 2026 Filed Apr 4, 2026 00:00 UTC | Apogee Therapeutics, Inc. APGE · Entity 1939 | SaleCommon Stock | 2,702 | $85.33 | $230,561.66 |
DisclosureSEC source: 0001104659-26-039709 · tm2611042-1_4seq1.xml · nonDerivative · entry 3 Dambkowski Carl · CIK 0001983476 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 208,498 F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 22, 2025. F3 · price: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $84.87 to $85.80, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| April 01, 2026 Filed Apr 4, 2026 00:00 UTC | Apogee Therapeutics, Inc. APGE · Entity 1939 | SaleCommon Stock | 2,698 | $84.31 | $227,468.38 |
DisclosureSEC source: 0001104659-26-039709 · tm2611042-1_4seq1.xml · nonDerivative · entry 2 Dambkowski Carl · CIK 0001983476 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 211,200 F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 22, 2025. F2 · price: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $83.87 to $84.84, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission ("SEC"), upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| April 01, 2026 Filed Apr 4, 2026 00:00 UTC | Apogee Therapeutics, Inc. APGE · Entity 1939 | Exercise / conversionCommon Stock | 4,125 | $22.86 | $94,297.50 |
DisclosureSEC source: 0001104659-26-039709 · tm2611042-1_4seq1.xml · nonDerivative · entry 1 Dambkowski Carl · CIK 0001983476 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 213,898 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 04, 2026 Filed Mar 7, 2026 01:00 UTC | Apogee Therapeutics, Inc. APGE · Entity 1939 | Exercise / conversionStock Option (Right to Buy) · Derivative | 4,125 | $0.00 Strike: $22.86 | $0.00 |
DisclosureSEC source: 0001104659-26-024831 · tm268128-1_4seq1.xml · derivative · entry 5 Dambkowski Carl · CIK 0001983476 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 131,290 Underlying: Common Stock · 4,125 shares Expires 2033-12-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: This option represents the right to purchase 175,345 shares of the Issuer's common stock, which will vest in forty-eight equal monthly installments through December 18, 2027, subject to the Reporting Person's continued service to the Issuer. Read SEC document |
| March 04, 2026 Filed Mar 7, 2026 01:00 UTC | Apogee Therapeutics, Inc. APGE · Entity 1939 | SaleCommon Stock | 200 | $73.26 | $14,652.00 |
DisclosureSEC source: 0001104659-26-024831 · tm268128-1_4seq1.xml · nonDerivative · entry 4 Dambkowski Carl · CIK 0001983476 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 209,773 F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 22, 2025. F4 · price: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $73.20 to $73.31, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| March 04, 2026 Filed Mar 7, 2026 01:00 UTC | Apogee Therapeutics, Inc. APGE · Entity 1939 | SaleCommon Stock | 2,075 | $71.98 | $149,358.50 |
DisclosureSEC source: 0001104659-26-024831 · tm268128-1_4seq1.xml · nonDerivative · entry 3 Dambkowski Carl · CIK 0001983476 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 209,973 F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 22, 2025. F3 · price: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $71.51 to $72.45, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| March 04, 2026 Filed Mar 7, 2026 01:00 UTC | Apogee Therapeutics, Inc. APGE · Entity 1939 | SaleCommon Stock | 3,225 | $70.33 | $226,814.25 |
DisclosureSEC source: 0001104659-26-024831 · tm268128-1_4seq1.xml · nonDerivative · entry 2 Dambkowski Carl · CIK 0001983476 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 212,048 F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 22, 2025. F2 · price: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $70.30 to $70.82, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission ("SEC"), upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| March 04, 2026 Filed Mar 7, 2026 01:00 UTC | Apogee Therapeutics, Inc. APGE · Entity 1939 | Exercise / conversionCommon Stock | 4,125 | $22.86 | $94,297.50 |
DisclosureSEC source: 0001104659-26-024831 · tm268128-1_4seq1.xml · nonDerivative · entry 1 Dambkowski Carl · CIK 0001983476 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 215,273 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 04, 2026 Filed Feb 5, 2026 01:02 UTC | Apogee Therapeutics, Inc. APGE · Entity 1939 | Exercise / conversionStock Option (Right to Buy) · Derivative | 4,125 | $0.00 Strike: $22.86 | $0.00 |
DisclosureSEC source: 0001104659-26-010454 · tm265045-2_4seq1.xml · derivative · entry 7 Dambkowski Carl · CIK 0001983476 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 135,415 Underlying: Common Stock · 4,125 shares Expires 2033-12-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_date: This option represents the right to purchase 175,345 shares of the Issuer's common stock, which will vest in forty-eight equal monthly installments through December 18, 2027, subject to the Reporting Person's continued service to the Issuer. Read SEC document |
| February 04, 2026 Filed Feb 5, 2026 01:02 UTC | Apogee Therapeutics, Inc. APGE · Entity 1939 | SaleCommon Stock | 200 | $68.94 | $13,788.00 |
DisclosureSEC source: 0001104659-26-010454 · tm265045-2_4seq1.xml · nonDerivative · entry 6 Dambkowski Carl · CIK 0001983476 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 211,148 F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 22, 2025. F6 · price: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $68.90 to $68.98, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| February 04, 2026 Filed Feb 5, 2026 01:02 UTC | Apogee Therapeutics, Inc. APGE · Entity 1939 | SaleCommon Stock | 100 | $67.88 | $6,788.00 |
DisclosureSEC source: 0001104659-26-010454 · tm265045-2_4seq1.xml · nonDerivative · entry 5 Dambkowski Carl · CIK 0001983476 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 211,348 F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 22, 2025. F5 · price: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $67.80 to $67.95, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| February 04, 2026 Filed Feb 5, 2026 01:02 UTC | Apogee Therapeutics, Inc. APGE · Entity 1939 | SaleCommon Stock | 1,299 | $66.85 | $86,838.15 |
DisclosureSEC source: 0001104659-26-010454 · tm265045-2_4seq1.xml · nonDerivative · entry 4 Dambkowski Carl · CIK 0001983476 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 211,448 F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 22, 2025. F4 · price: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $66.37 to $67.24, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| February 04, 2026 Filed Feb 5, 2026 01:02 UTC | Apogee Therapeutics, Inc. APGE · Entity 1939 | SaleCommon Stock | 1,420 | $65.83 | $93,478.60 |
DisclosureSEC source: 0001104659-26-010454 · tm265045-2_4seq1.xml · nonDerivative · entry 3 Dambkowski Carl · CIK 0001983476 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 212,747 F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 22, 2025. F3 · price: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $65.27 to $66.25, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| February 04, 2026 Filed Feb 5, 2026 01:02 UTC | Apogee Therapeutics, Inc. APGE · Entity 1939 | SaleCommon Stock | 2,481 | $64.88 | $160,967.28 |
DisclosureSEC source: 0001104659-26-010454 · tm265045-2_4seq1.xml · nonDerivative · entry 2 Dambkowski Carl · CIK 0001983476 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 214,167 F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 22, 2025. F2 · price: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $64.24 to $65.22, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission ("SEC"), upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| February 04, 2026 Filed Feb 5, 2026 01:02 UTC | Apogee Therapeutics, Inc. APGE · Entity 1939 | Exercise / conversionCommon Stock | 4,125 | $22.86 | $94,297.50 |
DisclosureSEC source: 0001104659-26-010454 · tm265045-2_4seq1.xml · nonDerivative · entry 1 Dambkowski Carl · CIK 0001983476 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 216,648 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 23, 2026 Filed Jan 23, 2026 21:31 UTC | Oruka Therapeutics, Inc. ORKA · Entity 3781 | OtherCommon Stock | 116,483 | $0.00 | $0.00 |
DisclosureSEC source: 0000907654-26-000013 · form4.xml · nonDerivative · entry 1 Dambkowski Carl · CIK 0001983476 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 116,483 F1 · kind: Represents the pro-rata distribution of shares of common stock for no consideration from a limited liability company in which the Reporting Person is a member. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.